The GLP-1 compounding era is ending. On April 30, 2026, the FDA formally proposed removing semaglutide, tirzepatide, and liraglutide from the 503B bulks list — the regulatory pathway that let outsourcing facilities mass-produce compounded versions of these drugs during the 2023–2024 shortages. If finalised, the proposal closes the last broad legal avenue for commercial-scale compounding of the biggest GLP-1 molecules on the market.
Key Takeaways
- April 30, 2026: FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list — finding "no clinical need" for outsourcing facilities to compound these drugs.
- Public comment period closed June 29, 2026. Final rule still pending as of October 2026; enforcement guidance already tightened in the meantime.
- 503A (patient-specific) compounding remains legal under existing rules — but at much smaller volume and under tighter prescription requirements.
- Shortages are over. FDA removed tirzepatide from the shortage list in October 2024 and semaglutide in February 2025. The 503B path only existed because of those shortages.
- March 2026: 30 FDA warning letters sent to telehealth companies in a single day for false or misleading claims about compounded GLP-1 products.
- Patient impact: Access through "GLP-1 clinics" that relied on 503B supply is contracting fast; branded Wegovy, Zepbound, and Mounjaro are back in full supply.
The 503A / 503B Distinction
Pharmaceutical compounding in the US sits on two legal pillars written into the Food, Drug & Cosmetic Act:
- Section 503A — Patient-specific compounding. A licensed pharmacist prepares a customised medication for one named patient based on a valid prescription. Volumes are small and the pharmacy is state-licensed.
- Section 503B — Outsourcing facilities. FDA-registered manufacturers that can compound drugs without patient-specific prescriptions, at commercial scale, provided the drug substance is on the FDA's "bulks list" or the drug is on the FDA shortage list.
During the 2023–2024 GLP-1 shortages, 503B facilities were allowed to mass-produce semaglutide and tirzepatide. The telehealth-powered weight-loss market that scaled from roughly $100M to several billion dollars in 24 months was built almost entirely on this exception.
What the April 2026 Proposal Does
The FDA's April 30, 2026 proposal would:
- Exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list, formally finding no clinical need for outsourcing facilities to compound from bulk substances when branded products are available.
- Close the mass-compounding pathway for these molecules at outsourcing facilities, regardless of whether they are later re-added to the shortage list.
- Not touch 503A patient-specific compounding directly — but 503A is bound by prescription requirements, volume caps, and state oversight, which collectively make scale-economy telehealth distribution much harder.
Public comment on the proposal closed June 29, 2026 via the federal docket. A final rule is expected to follow, with enforcement discretion already narrowing in the interim.
The Timeline So Far
- October 2024: FDA removes tirzepatide from the drug shortage list.
- February 2025: FDA removes semaglutide from the drug shortage list. 503B compounding of both drugs loses its shortage-based legal footing.
- December 2025: FDA signals intent to crack down on compounded GLP-1 marketing and importation claims.
- February 6, 2026: Formal FDA enforcement announcement.
- March 2026: 30 warning letters issued to telehealth companies in a single day for misleading compounded GLP-1 claims.
- April 30, 2026: Proposed 503B bulks-list exclusion published.
- June 29, 2026: Public comment period closes.
- October 2026 (current): Final rule pending; enforcement already tightening.
What This Means for Patients
The practical fallout:
- Branded availability is strong. Novo Nordisk and Eli Lilly have resolved manufacturing capacity. Wegovy, Zepbound, Mounjaro, and Ozempic are consistently stocked. The acute "patient can't get the drug" problem that justified compounding in 2023 no longer exists.
- Compounded prices will rise or exit. 503B economics depended on bulk production. Shifting back to 503A patient-specific prescribing removes most of the margin that let compounded GLP-1s undercut branded prices.
- Telehealth GLP-1 clinics are consolidating. Some have pivoted to branded prescriptions with insurance navigation; others have begun offering non-GLP-1 adjuncts (metformin, orlistat, lifestyle programs) or expanded into orforglipron prescribing as the first oral option approaches market.
- Peptide research market remains separate. The compounded GLP-1 crackdown is distinct from research peptide suppliers. However, the FDA's broader scrutiny of unapproved peptides (including BPC-157 and TB-500 category discussions by advisory committees) is proceeding in parallel.
What This Means for Research
For readers tracking the peptide research space, three things to note:
- The regulatory environment is tightening, not loosening. The FDA panel discussion in 2024 that advised against adding BPC-157 to the 503A bulks list sits in the same philosophical frame as the April 2026 503B exclusion — a general return to "approved drugs for human use, research compounds for research only."
- Branded GLP-1 is the comparator in future peptide trials. Expect direct head-to-head data (CagriSema vs. tirzepatide, retatrutide vs. tirzepatide, orforglipron vs. oral semaglutide) rather than placebo-only designs.
- Compounded sources are no longer an informal "cheaper branded" substitute. They are a different legal category with narrowing use cases.
Frequently Asked Questions
Does this proposal make compounded semaglutide illegal?
Not entirely. The April 2026 proposal targets 503B outsourcing facilities (mass-scale compounding). 503A patient-specific compounding remains legal, but it is bound by prescription requirements and small-batch limits that make it a much narrower pathway. Many of the large telehealth operators relied on 503B supply — their business model is directly affected.
When does this take effect?
The proposal was published April 30, 2026 and the public comment period closed June 29, 2026. A final rule is still pending as of October 2026. In the meantime, the FDA has used enforcement discretion and warning letters to narrow activity even before the rule is finalised.
Why did the FDA do this if GLP-1 drugs are already approved?
The 503B compounding allowance was created to let outsourcing facilities meet drug-shortage demand. Once the FDA formally confirmed the semaglutide and tirzepatide shortages were resolved (October 2024 and February 2025), the clinical justification for mass compounding disappeared. The April 2026 proposal formalises that finding and permanently removes the pathway, so future short-term shortages can't automatically re-open it.
Can I still get compounded tirzepatide from my doctor?
Only via a 503A patient-specific prescription — meaning your doctor must prescribe it for you by name, the pharmacist must prepare it individually, and there must be a documented clinical reason compounding is required rather than using the branded product. The large-volume, telehealth-driven supply chain that fed most compounded users is contracting.
Does this affect research peptides like BPC-157 or TB-500?
Not directly. The April 2026 proposal applies specifically to semaglutide, tirzepatide, and liraglutide. However, the FDA has signalled broader scrutiny of unapproved peptides, including research compounds marketed for human use. The regulatory direction is clearly toward tightening, not loosening.
Is orforglipron affected?
No — orforglipron is a small molecule, not a peptide, and will be sold as a branded Eli Lilly product. The 503B compounding pathway was never relevant to small-molecule drugs with branded supply.
What about CagriSema and retatrutide?
Neither drug is on the 503B bulks list because neither is approved yet. If they are approved in 2026–2027 and reach commercial supply, they will enter the market directly as branded products — compounding exceptions won't apply unless a future shortage opens the door.
Primary sources:
- Pharmacy Times — FDA Moves to Permanently Close the Door on Compounded GLP-1s
- Orrick — FDA Moves to Shut the Door on Large-Scale Compounding of GLP-1 Drugs
- HCPLive — FDA Proposes Exclusion of Multiple GLP-1 RAs from Bulks List
- McDermott+ — FDA Declares Upcoming Crackdown on GLP-1 Claims, Importation
- Sheppard Mullin — Above the Federal Floor: State Regulation of Compounded GLP-1s and Peptides
Research disclaimer: This article is a summary of regulatory developments for educational purposes. It does not constitute legal, medical, or regulatory advice. Readers with questions about specific compounded medications should consult a licensed pharmacist, physician, or healthcare attorney.
